Investing.comCodex · 实盘不做把握 4/10
北京时间·🕒 发布 08:56:42时区推断·⟳ 抓取 12:45:12·⚡ 决策 08-05 14:39:29 +1h54m·83.1 天前
Attovia Therapeutics IPO定价17美元、拟募资2.89亿美元
公司IPO发行1700万股、每股17美元，预计募资2.89亿美元并在Nasdaq以ATTO交易。
📄 原文Investing.com↗ 原文
Attovia Therapeutics prices upsized IPO at $17 per share
SpaceX shares fall on AI spending concerns; Musk says $1 trln revenue possible SAN CARLOS, Calif. - Attovia Therapeutic…
不做 Attovia Therapeutics（ATTO.US）
IPO首日定价与融资信息不足以形成事件交易，缺少可比较预期差和可验证二级市场价格。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-04 · 扩散 medium · price-in 风险 medium ↗
关键理由
- 公司IPO发行1700万股、每股17美元，预计募资2.89亿美元并在Nasdaq以ATTO交易。
- IPO定价本身主要是融资与上市事件，缺少上市后二级市场可回测价格、流动性和基本面超预期边界。
主要风险
- 新股首日波动高，正文没有给出估值、现金跑道或临床数据相对预期差。
工具调用 · 历史记录,结果未知(3 种)
- search_processed_events · 结果未知
- kb_search · 结果未知
- stock_quote · 结果未知
原文全文
展开原文 · 1,842 字
SpaceX shares fall on AI spending concerns; Musk says $1 trln revenue possible
SAN CARLOS, Calif. - Attovia Therapeutics, Inc. (NASDAQ:ATTO) announced Monday the pricing of its upsized initial public offering of 17,000,000 shares of common stock at $17.00 per share, according to a press release statement.
The clinical-stage biopharmaceutical company expects to receive gross proceeds of $289.0 million before deducting underwriting discounts, commissions and other offering expenses. All shares in the offering will be sold by Attovia.
The company granted underwriters a 30-day option to purchase up to an additional 2,550,000 shares at the initial public offering price, less underwriting discounts and commissions.
Attovia’s common stock is expected to begin trading on the Nasdaq Global Market today under the symbol ATTO. The offering is expected to close on August 6, 2026, subject to customary closing conditions.
Morgan Stanley, Leerink Partners, Citigroup and RBC Capital Markets are acting as joint book-running managers for the offering. LifeSci Capital is acting as a passive book-running manager.
The company develops biotherapeutics for immune-mediated diseases. Its lead programs include ATTO-1310, an anti-IL-31 therapeutic in clinical development for chronic pruritic diseases, ATTO-2306, a bispecific antibody targeting IL-31 and IL-13 in IND-enabling studies for atopic dermatitis and other immune-mediated skin diseases, and ATTO-1091, a trispecific antibody targeting TL1A, IL-23p19, and integrin α4β7 in IND-enabling studies for inflammatory bowel disease.
A registration statement relating to the securities was filed with the Securities and Exchange Commission and was declared effective on August 4, 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
SAN CARLOS, Calif. - Attovia Therapeutics, Inc. (NASDAQ:ATTO) announced Monday the pricing of its upsized initial public offering of 17,000,000 shares of common stock at $17.00 per share, according to a press release statement.
The clinical-stage biopharmaceutical company expects to receive gross proceeds of $289.0 million before deducting underwriting discounts, commissions and other offering expenses. All shares in the offering will be sold by Attovia.
The company granted underwriters a 30-day option to purchase up to an additional 2,550,000 shares at the initial public offering price, less underwriting discounts and commissions.
Attovia’s common stock is expected to begin trading on the Nasdaq Global Market today under the symbol ATTO. The offering is expected to close on August 6, 2026, subject to customary closing conditions.
Morgan Stanley, Leerink Partners, Citigroup and RBC Capital Markets are acting as joint book-running managers for the offering. LifeSci Capital is acting as a passive book-running manager.
The company develops biotherapeutics for immune-mediated diseases. Its lead programs include ATTO-1310, an anti-IL-31 therapeutic in clinical development for chronic pruritic diseases, ATTO-2306, a bispecific antibody targeting IL-31 and IL-13 in IND-enabling studies for atopic dermatitis and other immune-mediated skin diseases, and ATTO-1091, a trispecific antibody targeting TL1A, IL-23p19, and integrin α4β7 in IND-enabling studies for inflammatory bowel disease.
A registration statement relating to the securities was filed with the Securities and Exchange Commission and was declared effective on August 4, 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。